# Ipamorelin FAQ: Mechanism, Safety, Dosing, and Regulatory Status — Common Questions Answered

> Ipamorelin FAQ — 29 questions on mechanism, safety, pharmacokinetics, comparison peptides, and regulatory status, answered directly from the published preclinical and clinical literature.

**Q.01: What does Ipamorelin do?**
Ipamorelin acts as a selective agonist of the ghrelin receptor (GHS-R1a), triggering the anterior pituitary to release GH in discrete pulses. At doses more than 200-fold above the GH-releasing ED₅₀ in rats, it produces no significant elevation of ACTH, cortisol, prolactin, FSH, LH, or TSH [1]. GH pulse peak occurs at 15–40 minutes post-injection; return to baseline within approximately 3 hours [2].

**Q.02: What are the downsides of Ipamorelin?**
The main pharmacological concern is GH-independent adiposity: Lall et al. 2001 found that chronic GHS administration including ipamorelin increased fat pad weights regardless of GH status in mice, via a non-GH mechanism [8]. Regulatory concerns include WADA prohibition (S2, at all times) [9] and FDA prohibition from compounding pharmacy use after October 2024 [16].

**Q.03: Does Ipamorelin cause weight gain?**
In preclinical models the result depends on the model context. Bone and body-composition studies show increased body weight alongside lean mass accretion at studied doses [3, 4]. Lall et al. 2001 found increased fat pad weights through GH-independent mechanisms in mice [8]. Net weight change is not uniform across model types and dose ranges.

**Q.04: Will Ipamorelin raise testosterone levels?**
Ipamorelin does not directly stimulate testosterone production. The LH/FSH gonadotropin axis is not significantly engaged by GHS-R1a agonism at studied doses — FSH and LH remained unchanged in the Raun et al. 1998 hormonal panel [1].

**Q.05: Is tesamorelin better than Ipamorelin?**
Tesamorelin is FDA-approved for HIV-associated lipodystrophy and has clinical trial data showing approximately 15–18% visceral fat reduction at 26–52 weeks [13, 17]. Ipamorelin has preclinical selectivity data and one incomplete Phase 2 trial. They act on different receptor classes (GHRH-R vs. GHS-R1a), have not been tested head-to-head, and address different research endpoints. No comparative superiority is established in the published record.

**Q.06: Which is safer, Sermorelin or Ipamorelin?**
Both compounds avoid the cortisol/prolactin elevation seen with GHRP-2, GHRP-6, and hexarelin. Ipamorelin's selectivity was demonstrated across doses 200-fold above the GH-releasing ED₅₀ in rats [1]; sermorelin's adverse-event profile also shows no significant cortisol, prolactin, or insulin elevation at studied human doses [14]. No head-to-head safety comparison exists in a single controlled study.

**Q.07: Does Ipamorelin reduce belly fat?**
Animal studies report GH-mediated lipolytic signaling that could contribute to visceral fat reduction; however, Lall et al. 2001 found that GH secretagogues including ipamorelin can increase fat mass through GH-independent mechanisms at chronic doses [8]. No human visceral fat reduction study for ipamorelin exists in the reviewed literature. Body-composition effect is model-dependent.

**Q.08: What is the CJC-1295 Ipamorelin peptide good for?**
Co-administration is studied for additive GH pulse amplitude via dual-pathway activation. CJC-1295 (GHRH-R via Gαs/cAMP) primes somatotrophs; ipamorelin (GHS-R1a) triggers acute GH exocytosis per primed cell [10, 11]. Human CJC-1295 data shows 2–10-fold GH elevation in healthy adults [10]. Ipamorelin dual-pathway framing is research-context only.

**Q.09: How many times a week should you inject Ipamorelin and CJC-1295?**
Published preclinical protocols vary: once daily to three-times-daily injection intervals appear across ipamorelin bone and body composition studies [3, 4]. CJC-1295 in human trials was administered as single or multiple SC doses across weeks given its 5.8–8.1 day half-life [10]. No clinically recommended injection frequency exists — Ipamorelin has no approved human dosing protocol.

**Q.10: How long does it take to see results from Ipamorelin and CJC-1295?**
In rodent studies: GH pulse changes measured within 15–30 minutes of injection [2]; body weight and bone formation changes assessed over 3-month treatment windows [4]. No Ipamorelin-specific time-to-endpoint study in humans appears in the reviewed record.

**Q.11: What are the downsides to CJC-1295 Ipamorelin?**
CJC-1295-specific concerns from human trials include injection-site reactions; no major neuroendocrine disruption was reported at studied doses in healthy adults [10]. The Lall 2001 GH-independent adiposity caveat applies to GHS class effects broadly [8]. No approved co-administration protocol exists.

**Q.12: Can you take both Sermorelin and Ipamorelin together?**
Preclinical models study GHRH + GHRP co-administration to assess additive GH-pulse effects via the two complementary receptor pathways [14]. No approved co-administration protocol exists; framing is research-context only.

**Q.13: Is Ipamorelin FDA approved?**
No. Ipamorelin has not received FDA approval for any human indication. The Phase 2 clinical trial (NCT00672074) completed without an NDA submission [15]. The FDA PCAC voted against adding ipamorelin acetate to the 503A bulk drug substances list in October 2024 [16].

**Q.14: What is Ipamorelin peptide?**
Ipamorelin is a pentapeptide (five amino acids: Aib-His-D-2-Nal-D-Phe-Lys-NH₂), molecular weight 711.87 Da, synthesized by Novo Nordisk under the designation NNC 26-0161. It selectively binds GHS-R1a receptors on anterior pituitary somatotrophs to stimulate pulsatile GH release [1].

**Q.15: What does Ipamorelin peptide do?**
Ipamorelin binds GHS-R1a via Gq/11-coupled phospholipase C and intracellular calcium mobilization to amplify pulsatile GH secretion while suppressing somatostatin tone. Unlike earlier GHRPs, it produces GH pulses without cortisol, prolactin, or aldosterone elevations at stimulating doses [1].

**Q.16: Does Ipamorelin make you hungry?**
Single-dose administration in Venkova et al. 2009 produced no significant food intake change at 48 hours in rodent models [5]. The endogenous ghrelin appetite signal does not appear to be carried through fully by ipamorelin's selective GHS-R1a engagement at single or low doses.

**Q.17: Does Ipamorelin increase appetite?**
No food intake increase was observed after single-dose administration in surgical models [5]. Appetite effects were observed only with repetitive dosing in energy-depleted post-surgical animals — a context-specific finding, not a general orexigenic profile.

**Q.18: How long does Ipamorelin stay in your system?**
Plasma half-life approximately 2 hours in rodent pharmacokinetic data [2]. 60–80% recoverable intact from urine; free-acid metabolites persist after parent compound clears — the basis for the WADA detection window (Semenistaya et al. 2015) [9].

**Q.19: How does Ipamorelin work?**
Ipamorelin mimics ghrelin at GHS-R1a, activating Gq/11-coupled phospholipase C in somatotroph cells to mobilize intracellular Ca²⁺, triggering GH vesicle exocytosis. It also suppresses hypothalamic somatostatin [1]. Each pulse peaks at 15–40 minutes post-SC-injection and returns to baseline within approximately 3 hours [2].

**Q.20: What is the difference between Sermorelin and Ipamorelin?**
Sermorelin: GHRH 1-29 fragment acting on GHRH-R via Gαs/cAMP/PKA, plasma half-life 11–12 minutes [14]. Ipamorelin: ghrelin mimetic acting on GHS-R1a via Gq/Ca²⁺, plasma half-life approximately 2 hours [2]. Distinct receptor classes, distinct G-protein pathways, distinct half-lives [1, 14].

**Q.21: Is Ipamorelin a peptide?**
Yes. Ipamorelin is a five-amino-acid peptide (pentapeptide): Aib-His-D-2-Nal-D-Phe-Lys-NH₂, molecular weight 711.87 Da. Its synthesis preceded the discovery of endogenous ghrelin (1999) [1].

**Q.22: When is the best time to take Ipamorelin?**
Preclinical protocols vary administration timing without establishing a definitive optimum. The Andersen et al. 2001 bone study used three-times-daily SC injection over 3 months [4]. No human protocol exists for this compound.

**Q.23: Can women use Ipamorelin in research models?**
Both male and female animal subjects appear in published ipamorelin studies. The Johansen 1999 and Andersen 2001 bone studies used adult female rats [3, 4]; Jiménez-Reina 2002 used young female rats [7]. Sex-specific GH secretion differences are a documented variable [7].

**Q.24: Does Ipamorelin cause water retention?**
GH-mediated fluid retention is a known class effect for GH-elevating interventions. Ipamorelin's physiological-range GH pulses produce a lower edema signal than direct recombinant GH administration in rodent study observations. Minimal edema is reported at ipamorelin's studied dose ranges.

**Q.25: Is Ipamorelin better than Sermorelin?**
No head-to-head controlled study exists. Mechanistically: ipamorelin's GHS-R1a selectivity avoids cortisol/prolactin elevation across a wider demonstrated dose range [1]; sermorelin's GHRH-R mechanism supports tonic GH secretion patterns with an 11–12 minute half-life [14]. Compound-level superiority is not supported by the published record.

**Q.26: How long for Ipamorelin to work?**
GH pulse onset: 15–30 minutes post-injection in rat models [2]. GI motility changes: within hours in post-surgical models [5, 6]. Body-composition and bone formation endpoints: 4–12 week treatment windows [3, 4].

**Q.27: What does Ipamorelin do for growth hormone?**
Ipamorelin amplifies pulsatile GH secretion by binding GHS-R1a and mobilizing intracellular calcium in somatotrophs, while suppressing somatostatin tone. GH area-under-curve increases of 2–10-fold relative to baseline are studied at various doses and species [10, 11].

**Q.28: What is ipamorelin used for in research?**
GH-deficiency and growth deficit models [3, 4, 7]; post-surgical GI recovery [5, 6, 15]; body composition in GH-axis-deficient models [8, 12]; receptor pharmacology selectivity profiling [1]; anti-doping metabolite characterization for WADA detection [9].

**Q.29: How does the Ipamorelin and CJC-1295 stack work?**
CJC-1295 activates GHRH-R via Gαs/cAMP to prime somatotroph cells; ipamorelin activates GHS-R1a via Gq/Ca²⁺ to trigger acute GH exocytosis. The two pathways are mechanistically orthogonal. Human CJC-1295 data shows 2–10-fold GH elevation and preserved pulsatile architecture [10, 11].

## References

[1] Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561.
[2] Johansen PB, et al. Pharmacokinetic evaluation of ipamorelin. Xenobiotica. 1998;28(12):1235-1248.
[3] Johansen PB, et al. Ipamorelin induces longitudinal bone growth in rats. Growth Horm IGF Res. 1999;9(2):106-113.
[4] Andersen NB, et al. Ipamorelin counteracts glucocorticoid-induced decrease in bone formation. Growth Horm IGF Res. 2001;11(5):266-272.
[5] Venkova K, et al. Efficacy of ipamorelin in a rodent model of postoperative ileus. J Pharmacol Exp Ther. 2009;329(3):1110-1116.
[6] Greenwood-Van Meerveld B, et al. Efficacy of ipamorelin on gastric dysmotility. J Exp Pharmacol. 2012;4:149-155.
[7] Jiménez-Reina L, et al. Influence of chronic ipamorelin treatment in young female rats. Histol Histopathol. 2002;17(3):707-714.
[8] Lall S, et al. GH-independent stimulation of adiposity by GH secretagogues. Biochem Biophys Res Commun. 2001;280(1):132-138.
[9] Semenistaya E, et al. GHRP metabolites in human urine after nasal administration. Drug Test Anal. 2015;7(11-12):1014-1019.
[10] Teichman SL, et al. Prolonged Stimulation of GH and IGF-I by CJC-1295. J Clin Endocrinol Metab. 2006;91(3):799-805.
[11] Ionescu M, Frohman LA. Pulsatile GH secretion persists during CJC-1295 stimulation. J Clin Endocrinol Metab. 2006;91(12):4792-4797.
[12] Sinha DK, et al. Beyond the androgen receptor: GH secretagogues in body composition management. Transl Androl Urol. 2020;9(Suppl 2):S149-S159.
[13] Dhillon S. Spotlight on tesamorelin in HIV-associated lipodystrophy. BioDrugs. 2011;25(5):337-338.
[14] Ishida J, et al. Growth hormone secretagogues: history, mechanism of action, and clinical development. JCSM Rapid Commun. 2020;3(1):25-37.
[15] Helsinn Therapeutics. NCT00672074. ClinicalTrials.gov. 2017.
[16] FDA Pharmacy Compounding Advisory Committee. Briefing document. 2024.
[17] Meta-analysis of tesamorelin RCTs. Diabetes Res Clin Pract. 2026;222:112113.

---

A grid-indexed literature digest on Ipamorelin — nineteen primary findings, clean GH pulses, and no commercial position on any of them.